Atopic Dermatitis affects more than the skin—it disrupts sleep, mood, and daily life.
The toll includes missed work and school, hospital visits, and rising personal costs, especially for caregivers.1
The prevalence of atopic dermatitis varies globally, with North America standing out for its particularly high rates, along with Northern and Western Europe.2
Skin health has seen over 100% growth in recent years, securing its position among the top ten global probiotic segments, according to Lumina.3
The global skincare supplement market is expected to reach USD 4.5 billion by 2034, growing at a CAGR of 8.8% from 2024 to 2034.4
Atopic dermatitis (AD) is a chronic inflammatory condition that significantly impacts quality of life. Modulating the intestinal microbiota with probiotics has shown promise in alleviating or preventing its symptoms.
Central to this approach is the gut-skin axis, which represents the bidirectional relationship between gut health and skin condition, regulated through inflammation and immune responses, crucial for managing AD.
Vigiis® 101-LAB is designed to effectively promote the generation of regulatory T cells (Treg), as well as Th1/Th2 balance, which play a crucial role in regulating immune responses. This helps reduce excessive immune reactions and inflammation, thereby alleviating skin discomfort.5
Allergy Relief -SCORAD alleviation
During the skin irritation period, allergic symptoms in mice receiving Vigiis® 101-LAB were 25.6% lower than those in the control group. Better results in the second OVA skin stimulation showed the Vigiis® 101-LAB group with a 48.2% reduction in inflammation severity and a faster recovery time.
Itch Relief -TSLP diminution
The Major symtom of atopic skin is unberable itch. TSLP (thymic stromal lymphopoietin) has been widely recognized as a key molecule behind itch. If we can lower TSLP levels in the skin, there’s a good chance the itch can be significantly reduced.
Vigiis® 101-LAB reduces TSLP expression in dermatitis by 68%, ultimately improving symptoms of atopic dermatitis.
Skin Thickness Decrease (epidermal & dermal)
Persistent allergic reactions and inflammation promote the proliferation of keratinocytes, leading to
thickening of the epidermis. At the same time, inflammation triggers the proliferation of fibroblasts in the dermis, resulting in thickening of the dermis.
Vigiis® 101-LAB reduces epidermal thickness by 23% and dermal thickness by 50%, effectively lessen-ing skin thickening and easing atopic dermatitis symptoms.
Regulatory T cell Elevation and IgE Decrease
Regulatory T cells (Tregs) are key to maintaining immune homeostasis and controlling IgE levels. In atopic conditions, Treg dysfunction leads to elevated IgE and increased symptoms.Vigiis® 101-LAB promotes Treg maturation by 115% and lowers IgE production by 25%, offering a targeted approach for immune-based skin health formulations.”
The recommended dose of MonaFit for a healthy adult is one unit daily according to specific requirements.
Benefits of Vigiis®101-LAB for Skin Health:
Market-Ready Formula Concepts
The Scientifically Proven, Market-Ready Solution to Set Your Products Apart and Accelerate Your Success
Vigiis 101-LAB PRODUCT CONCEPTS
Ingredient:
Vigiis 101-LAB
Application:
Supports body balance*
Enhances gut microbiome health*
Promotes healthy digestion*
Helps boost metabolism*
Vigiis 101-LAB PRODUCT CONCEPTS
Ingredient:
Vigiis 101-LAB
Application:
Supports body balance*
Enhances gut microbiome health*
Promotes healthy digestion*
Helps boost metabolism*
The communication is intended for business-to-business information and not for the final consumer. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
